Niloufar Mobashery

Statistics

Publications

Citations

1.1K

H-Index

Active since

1997

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Université Paris Cité

AbbVie (United States)

Inserm

Cornell University

Niloufar Mobashery is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in virology, antiviral therapy, and pharmacotherapy.

Publications per year

1997–2017

Publications

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

Christophe Hézode, Tarik Asselah, K. Rajender Reddy et al. · The Lancet · 2015 · 258 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Disseminated Leishmaniasis: A New and Emerging Form of Leishmaniasis Observed in Northeastern Brazil

Meredith L. Turetz, Paulo Roberto Lima Machado, Albert I. Ko et al. · The Journal of Infectious Diseases · 2002 · 196 citations · Full text

Veterinary Medicine, Dermatology, Infectious Diseases +17

The conformational preference of gramicidin channels is a function of lipid bilayer thickness<sup>1</sup>

Niloufar Mobashery, Claus Hélix‐Nielsen, O.S. Andersen · FEBS Letters · 1997 · 123 citations

Natural Sciences, Biochemistry, Biophysics +17

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

Eric Lawitz, Mihály Makara, Ulus Salih Akarca et al. · Gastroenterology · 2015 · 85 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial

Imam Waked, Gamal Shiha, Roula Qaqish et al. · The Lancet. Gastroenterology & hepatology · 2016 · 74 citations

Medicine, Infectious Diseases, Pharmacotherapy +16

1–5 of 20